Drugs / ⁸⁹Zr-Df-IAB22M2C
⁸⁹Zr-Df-IAB22M2C
Trials 6 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 14 trials | ||||||
| Phase 1 | NCT05849467 | Oct 2023 → Apr 2030 expected | multiple sclerosis, progressive multifocal leukoencephalopathy | National Institute of Neurological Disorders and Stroke (NINDS) | Recruiting | No outcome recorded |
| Phase 1 | NCT05371132 | Jun 2022 → Oct 2026 expected | lymphoma, metastatic malignant neoplasm | City of Hope Medical Center | Recruiting | No outcome recorded |
| Phase 1 | NCT04955262 | Aug 2019 → Jun 2021 | metastatic melanoma | Nektar Therapeutics | Withdrawn | No outcome recorded |
| Phase 1 | NCT03107663 | Jun 2017 → Aug 2018 | Hodgkins lymphoma, metastatic malignant neoplasm | ImaginAb, Inc. | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT05013099 | Dec 2021 → Jul 2025 overdue | cutaneous neuroendocrine carcinoma, melanoma, non-small cell lung carcinoma, renal cell carcinoma | ImaginAb, Inc. | Active not recruiting | No outcome recorded |
| Phase 2 | NCT03802123 | Dec 2018 → Oct 2021 | metastatic neoplasm | ImaginAb, Inc. | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 89Zr-Df-IAB22M2C | “Patients received 111 MBq of 89Zr-Df-IAB22M2C followed by serial PET scanning over 5-7 d.” PMID 34413145 ↗ Aug 2021 |
| Known as | 89Zr-Df-crefmirlimab | “89Zr-Df-crefmirlimab, an investigational, intravenous PET tracer” NCT05849467 ↗ |
| Known as | zirconium Zr 89 crefmirlimab berdoxam | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05013099 ↗ |
| Known as | Zirconium Zr 89-Df-Crefmirlimab | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05371132 ↗ |
| Modality | Diagnostic / imaging agent | “CD8 T cell tracer for Positron Emission Tomography (PET)” NCT03802123 ↗ |
| Route | Intravenous | “will be administered intravenously over 5-10 minutes” NCT03107663 ↗ |